Shanghai RAAS Blood Products Co., Ltd. (SHE:002252)
China · Delayed Price · Currency is CNY 5.66
-0.02 (-0.35%)
Apr 14, 2026, 3:04 PM CST
SHE:002252 Revenue
In the year 2025, Shanghai RAAS Blood Products had annual revenue of 7.35B CNY, down -10.13%. Shanghai RAAS Blood Products had revenue of 1.26B in the quarter ending December 31, 2025, a decrease of -32.49%.
Revenue
7.35B
Revenue Growth
-10.13%
P/S Ratio
5.05
Revenue / Employee
2.19M
Employees
4,045
Market Cap
37.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.35B | -828.28M | -10.13% |
| Dec 31, 2024 | 8.18B | 212.50M | 2.67% |
| Dec 31, 2023 | 7.96B | 1.40B | 21.27% |
| Dec 31, 2022 | 6.57B | 2.28B | 53.16% |
| Dec 31, 2021 | 4.29B | 1.53B | 55.26% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pharmaron Beijing | 14.10B |
| Chongqing Zhifei Biological Products | 10.91B |
| Asymchem Laboratories (Tianjin) | 6.67B |
| Beijing Tiantan Biological Products | 6.17B |
| Shanghai Allist Pharmaceuticals | 5.17B |
| Hualan Biological Engineering | 4.60B |
| Sunshine Guojian Pharmaceutical (Shanghai) | 4.20B |
| Xiamen Amoytop Biotech | 3.70B |